A detailed history of M&T Bank Corp transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 5,271 shares of APLS stock, worth $184,379. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,271
Previous 4,680 12.63%
Holding current value
$184,379
Previous $280,000 10.36%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$55.39 - $72.47 $32,735 - $42,829
591 Added 12.63%
5,271 $309,000
Q4 2023

Feb 06, 2024

BUY
$37.14 - $64.82 $173,815 - $303,357
4,680 New
4,680 $280,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.84B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.